The NHS landscape is changing, as now set out by the Government’s White Paper and the forthcoming legislation. What will it mean for the future funding and adoption of medicines?
- High cost drugs either had a funding route from NHS England via specialised commissioning or CCGs. With the withdrawal of CCGs, where does this leave the process for drugs that were previously funded by them?
- Specialised commissioning is also on the move and we await the results of the shift in responsibilities from NHS England to Integrated Care Systems and attached clinical networks – how is this likely to work?
- Place and provider collaboratives will be key to the new NHS – what role will they have on drugs decision-making, how will medicines affect their budgets and what will their considerations be in using existing and new therapies?
- Medicines optimisation will also be a huge factor in the new environment – who is running this at regional, system, place and neighbourhood level, and what impact could it have on prescribing?
- High-cost drugs pharmacists and clinical pharmacists – what role will they have on formulary and medicines use?
- And what of the future of centralised procurement, centralised drugs funds, innovation schemes and ringfenced funding? How will they fit into the overall picture?
Wilmington Healthcare is pleased to bring you an exclusive review of the raft of medicines funding changes coming into the English healthcare system.
Our review will look at:
Funding flows, including the new expectations for high cost drugs, hospital-dispensed drugs and those included in tariff.
Budget-holders, at national, regional, system and place level: how does this work in the world of contracted services and where will drugs budgets sit?
Decision-makers and stakeholders within the medicines space.
Market access issues, such as sub-national HTA, system formularies and autonomous decision-making and interpretation of formularies issues at place level.
Based on our own research and interviews with commissioning and specialised commissioning decision-makers, high cost drugs specialists and pharmacists, the review will also contain valuable datasets of the new decision makers, enabling you to segment, identify and begin to engage with them.
- clinical service directors
- high-cost drugs pharmacists
- programme managers for specific disease areas and clinical leads
- staff working in medicines management and medicines optimisation
Our review also includes process flow diagrams, maps and organisational charts to help ensure that you and your company understand these changes and how they will affect your engagement with the NHS.